Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTELLANCE-2: ABT-414 in recurrent glioblastoma
NCT02343406Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Feb 2015
- Primary completion
- Jun 2019
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 21
01
Overview
Phase 2, randomised, open-label trial of depatuxizumab mafodotin in glioblastoma (GBM) (5 arms), sponsored by AbbVie Inc. Primary endpoints: Overall Survival at 28 months, Progression-Free Survival at 2 years and 2 more. Started Feb 2015; status: completed.
02
Drugs
depatuxizumab mafodotin
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02343406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02343406.